ClinPhenomics CVC GmbH
- Address
- lock Available on a paid plan
ClinPhenomics CVC GmbH
ClinPhenomics CVC GmbH is a specialized clinical research center with expertise in cardiovascular disease research, particularly focusing on advanced heart failure therapeutics. The center plays a vital role in conducting pivotal clinical trials that evaluate novel interventions for patients with complex cardiac conditions.
- Chronic heart failure with reduced ejection fraction (HFrEF) treatment strategies
- Cardiovascular mortality and hospitalization risk reduction studies
- Evaluation of innovative pharmacological interventions for heart failure
The center has demonstrated particular proficiency in chronic heart failure with reduced ejection fraction research, contributing to large-scale efficacy trials that assess the impact of emerging therapies on critical outcomes including cardiovascular death and heart failure hospitalization. ClinPhenomics CVC GmbH's involvement in comprehensive cardiovascular trials positions them as an important contributor to advancing evidence-based treatment options for patients living with advanced heart failure.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB3active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ClinPhenomics CVC GmbH
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a) | Novartis Pharma AG | Phase II | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pelacarsen | 3 | Unknown | 2020-03-06 | 2026-05-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.